Tenofovir Gel

The CAPRISA 004 trial to assess the effectiveness and safety of a vaginal gel containing the antiretroviral drug tenofovir for the prevention of HIV infection in women in South Africa was completed in 2010 and the results were presented at the XVIIIth International AIDS Conference in Vienna, Austria, in June 2010.